NeopharmCO.,LTD.
Financials
Valuation Metrics
NeopharmCO.,LTD.'s Market Cap is ₩3662B. At end of 2025 it was ₩2944B. Ranked #569 of 2,421 in KR market (top 24%), #226 of 1,640 on KOSDAQ (top 14%), #11 of 57 in Household & Personal Products (top 19%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 366.24B KRW | KR#569/2,421 Sec#11/57 |
| Revenue | 148.39B KRW | KR#1,191/2,421 Sec#26/57 |
| Net Income | 30.65B KRW | KR#557/2,421 Sec#14/57 |
| Total Assets | 217.81B KRW | KR#1,250/2,421 Sec#26/57 |
| Net Assets | 195.36B KRW | KR#958/2,421 Sec#19/57 |
| Employees | 171 | KR#1,213/2,421 Sec#27/57 |
| Value | ||
| P/E | 11.95x | KR#923/2,421 Sec#23/57 |
| P/B | 1.87x | KR#1,904/2,421 Sec#44/57 |
| PEG | 0.56x | KR#703/2,421 Sec#23/57 |
| P/S | 2.47x | KR#1,907/2,421 Sec#49/57 |
| EV/EBITDA | 10.48x | KR#645/2,421 Sec#14/57 |
| FCF Yield | 7.43% | KR#713/2,421 Sec#14/57 |
| Profitability | ||
| ROE | 15.69% | KR#291/2,421 Sec#12/57 |
| ROA | 14.07% | KR#134/2,421 Sec#5/57 |
| Op. Margin | 21.89% | KR#137/2,421 Sec#2/57 |
| Revenue Growth | 19.89% | KR#557/2,421 Sec#13/57 |
| Earnings Growth | 21.27% | KR#694/2,421 Sec#23/57 |
| Financial Health | ||
| Debt Ratio | 11.49% | KR#177/2,421 Sec#5/57 |
| Total Debt | 1.06B KRW | KR#1,952/2,421 Sec#47/57 |
| FCF | 27.23B KRW | KR#437/2,421 Sec#10/57 |
| Cash | 26.82B KRW | KR#1,067/2,421 Sec#22/57 |
| Net Debt/EBITDA | -0.79x | KR#421/2,421 Sec#10/57 |
| Dividend | ||
| Div. Yield | 3.28% | KR#579/2,421 Sec#12/57 |
| Div. Growth | 25.00% | KR#391/2,421 Sec#11/57 |
| Performance | ||
| 1Y Return | 23.85% | KR#401/2,421 Sec#8/57 |
| 1M Return | -1.51% | KR#1,419/2,421 Sec#27/57 |
| From 52W High | -12.12% | KR#101/2,421 Sec#2/57 |
| 1Y MDD | -28.85% | KR#217/2,421 Sec#4/57 |
| Trading | ||
| Volume | 48,998 shares | KR#1,145/2,421 Sec#29/57 |
| Trading Value | 1.13B KRW | KR#678/2,421 Sec#18/57 |
| Foreign Own. | 27.74% | KR#134/2,421 Sec#6/57 |
| Per Share | ||
| EPS | 1,912 KRW | KR#465/2,421 Sec#12/57 |
| BPS | 12,188 KRW | KR#842/2,421 Sec#18/57 |
Company Info
Established in 2000, the company is a KOSDAQ-listed cosmetics manufacturer. Its largest shareholder became It's Hanbul after the 2017 merger of Hanbul Cosmetics and It's Skin. The company owns cosmetic brands such as Atopalm, Real Barrier, Derma:B, Tl's, and Zeroid, with 83% domestic sales and 17% exports. Utilizing its proprietary MLE formulation technology, it develops products by understanding skin barrier function and expands its business through new formulation development. Neopharm is headquartered in Yuseong-gu, Daejeon.